Am Heart J:心梗后大剂量服用多种维生素和矿物质可能有意外之喜

2018-01-22 王淳 环球医学资讯

2018年1月,发表在《Am Heart J》的一项由于美国科学家进行的研究,在评估螯合疗法的随机试验(TACT)中,考察了大剂量口服多种维生素和矿物质的作用。

2018年1月,发表在《Am Heart J》的一项由于美国科学家进行的研究,在评估螯合疗法的随机试验(TACT)中,考察了大剂量口服多种维生素和矿物质的作用。

重要性:在TACT中基线时未使用他汀疗法受试者的一项预先设定的亚组分析中,发现大剂量复合口服多种维生素和多种矿物质方案比安慰剂具有较大的非预期的益处。本研究中考察的方案与先前临床试验考察的任何维生素方案存在明显不同。

目的:为探讨这些结果,研究人员对TACT纳入的未使用他汀的受试者开展了详细的额外分析。

设计:TACT是一项析因试验,在≥50岁心肌梗死(MI)后患者中,考察螯合治疗和28种成分的大剂量口服多种维生素和多种矿物质方案 vs 安慰剂。

受试者:基线时1708名TACT受试者中有460名(27%)未使用他汀,活性维生素组有224名(49%)患者,安慰剂组有236名(51%)患者。

地点:在美国和加拿大的134个机构纳入患者。

干预:每日高剂量口服多种维生素和多种矿物质(6片,活性药或安慰剂)。

主要结局:TACT的主要终点是复合终点中任意一项首次出现的时间:全因死亡率、MI、卒中、冠状动脉血管重建术或因心绞痛住院。

结果:137名未使用他汀的受试者(30%)出现主要终点,活性组224名患者中有51名(23%),安慰剂组236名患者中有86名(36%)(风险比[HR],0.62;95%置信区间[CI],0.44~0.87;P=0.006)。对于关键TACT次要终点结果、心血管死亡率、卒中或MI复发的复合结果,活性维生素组均有利(HR,0.46;95% CI,0.28~0.75;P=0.002)。多个终点分析与这些结果一致。

结论和相关性:在一个基线时未使用他汀治疗的稳定、MI后人群中,大剂量口服多种维生素和多种矿物质补充剂似乎能降低合并的心脏事件。这些非预期的结果正在TACT2中进行重新测试。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053408, encodeId=e886205340812, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue May 01 07:04:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290376, encodeId=6c1a2903e6ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sat Feb 24 06:30:04 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356655, encodeId=1626135665523, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562805, encodeId=e31f1562805fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578679, encodeId=350515e86794a, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-05-01 lfyang
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053408, encodeId=e886205340812, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue May 01 07:04:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290376, encodeId=6c1a2903e6ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sat Feb 24 06:30:04 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356655, encodeId=1626135665523, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562805, encodeId=e31f1562805fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578679, encodeId=350515e86794a, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-02-24 秀红

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2053408, encodeId=e886205340812, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue May 01 07:04:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290376, encodeId=6c1a2903e6ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sat Feb 24 06:30:04 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356655, encodeId=1626135665523, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562805, encodeId=e31f1562805fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578679, encodeId=350515e86794a, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-01-24 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2053408, encodeId=e886205340812, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue May 01 07:04:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290376, encodeId=6c1a2903e6ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sat Feb 24 06:30:04 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356655, encodeId=1626135665523, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562805, encodeId=e31f1562805fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578679, encodeId=350515e86794a, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
    2018-01-24 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=2053408, encodeId=e886205340812, content=<a href='/topic/show?id=93255105e89' target=_blank style='color:#2F92EE;'>#心梗后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51057, encryptionId=93255105e89, topicName=心梗后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Tue May 01 07:04:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290376, encodeId=6c1a2903e6ef, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Sat Feb 24 06:30:04 CST 2018, time=2018-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356655, encodeId=1626135665523, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562805, encodeId=e31f1562805fb, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578679, encodeId=350515e86794a, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Wed Jan 24 12:04:00 CST 2018, time=2018-01-24, status=1, ipAttribution=)]

相关资讯

JACC:心梗后的炎性反应对大脑和心脏的功能有明显影响

急性心梗后的局部炎性组织反应对最后的预后结果起到重要作用,全身作用引起的神经性炎症是神经退行性疾病的前兆。本研究的目的旨在通过非侵入性的正电子发射断层扫描(PET)评估心梗对心脏和大脑炎性反应的影响。本研究在对小鼠进行冠脉结扎或者假手术处理后,对所有小鼠(n=49)进行了全身线粒体转运蛋白(TSPO)的PET扫描,TSPO作为标记激活巨噬细胞和小胶质细胞的标志物,同时,急性心梗后的病人(n=3)也

心梗救治再加速,我们还能做什么?

追逐时间的心梗抢救,追寻着更快诊断、更快服药、更快起效,快快快下,我们还能做些什么?

中国医科大学附属盛京医院学者:血小板体积还能预测急性心梗介入后死亡风险

中国医科大学附属盛京医院学者发现,对于接受经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者来说,入院时平均血小板体积增高提示全因死亡和心原性死亡风险增加

JACC:无症状的心梗发生心衰的风险就低了吗?

尽管寂静型心肌梗死(SMI)占了心梗患者的近一半,但是目前对于SMI患者发生心衰的风险如何尚属未知。本研究的目的旨在比较评估SMI患者与有临床症状的心梗(CMI)患者发生心衰的相关性。本研究纳入了ARIC临床研究中的9243名无基础心血管疾病的研究对象,寂静型心梗定义为超声心动图提示有心梗但是无临床症状。在ARIC随访1期和4期期间,共有305名SMI患者和331CMI患者,ARIC4期临床研究之

Am Heart J:肾功能是否影响ST段抬高心梗患者药物干预策略的有效性或安全性?

2017年11月,发表在《Am Heart J》的一项meta分析,对肾功能是否影响ST段抬高心肌梗塞(STEMI)患者药物干预策略的有效性或安全性进行了考察。

JAHA:女性急性心梗患者的超额死亡率更高!

本研究的目的旨在评估急性心肌梗死治疗、全因死亡率、相对存活率和超额死亡率的性别差异。本研究纳入分析了瑞典2003年至2013年接受住院治疗的急性心肌梗死病人,在经年龄和住院时间等因素调整分析后,在全因死亡率方面无明显性别差异,在ST段抬高型心梗(STEMI)和非ST段抬高型心梗的并发症中也无明显的性别差异,但是在STEMI和非STEMI的1年和5年超额死亡率方面,女性要更高(1年:1.89 [95